Cognito Therapeutics Raises $105M in Series C Funding to Advance Alzheimer’s Neuromodulation Therapy

Back in 2016, a question about the brain refused to leave the room. Ed Boyden and Li-Huei Tsai were chasing a strange signal inside neural circuits, gamma rhythms at 40 Hz, a pulse of light and sound that in early research seemed to wake neurons up like a late-night jazz set suddenly finding its groove. Most people heard noise. They heard possibility. That curiosity turned into Cognito Therapeutics, a Cambridge company building a noninvasive neuromodulation therapy designed to slow the brutal march of Alzheimer’s disease.

Fast forward and the market just leaned in. Cognito Therapeutics has secured $105M in an oversubscribed Series C round led by Morningside Ventures with participation from IAG Capital Partners, Starbloom Capital, New Vintage, Apollo Health Ventures, and Benvolio Group. Serious investors tend to follow serious science, and this one comes with receipts. The company’s Spectris therapy uses synchronized light and sound stimulation to drive gamma frequency brain activity, aiming to address Alzheimer’s through neural rhythm rather than a syringe.

The leadership team knows exactly what game they’re playing. CEO Christian Howell stepped in with a mandate to move this platform from promising science to real-world scale. Jaclyn Lautz joined as SVP of Engineering in Q4 2025, helping translate elegant neuroscience into systems patients can actually use at home. Chandran Seshagiri, VP of R&D and former interim CTO, continues to drive the company’s manufacturing strategy and roadmap for expanding into future indications. Alongside them are CMO Ralph Kern, CFO Steve Worthy, and CCRO Robbert Zusterzeel, a group built less like a startup science project and more like a team gearing up for a commercial moment. And the team isn’t done building. Expect a few more key leadership additions to step on stage in the coming weeks and months.

The technology itself reads like science fiction written by someone who actually brought the data. Spectris delivers synchronized auditory and visual stimulation to nudge the brain into that 40 Hz gamma rhythm discovered in the original MIT work. Early clinical programs such as OVERTURE suggested measurable impact on cognitive decline and brain structure. Now the pivotal HOPE study has enrolled 670 patients across 70 sites in the United States, positioning Cognito to chase one of the most important regulatory moments in modern neurotechnology.

Here is the quiet business lesson hiding inside the science. Investors do not write nine figure checks because a company sounds smart. They invest because the founders built a credible bridge from discovery to device, from experiment to evidence. Cognito Therapeutics did the long grind first. Publish the science. Build the platform. Run the trials. Then raise the capital when the signal gets loud enough that the market can hear it too.